Journal of the American Chemical Society
Page 10 of 13
Collaborative Group (EBCTCG). Lancet 2015, 386 (10001),
1353-1361.
29.
Monkkonen, H.; Rogers, M. J.; Makkonen, N.; Niva,
1
2
3
4
5
6
7
8
S.; Auriola, S.; Monkkonen, J., The cellular uptake and
metabolism of clodronate in RAW 264 macrophages.
Pharm. Res. 2001, 18 (11), 1550-1555.
19.
Hadji, P.; Coleman, R. E.; Wilson, C.; Powles, T. J.;
Clézardin, P.; Aapro, M.; Costa, L.; Body, J.-J.; Markopoulos,
C.; Santini, D.; Diel, I.; Di Leo, A.; Cameron, D.; Dodwell, D.;
Smith, I.; Gnant, M.; Gray, R.; Harbeck, N.; Thurlimann, B.;
Untch, M.; Cortes, J.; Martin, M.; Albert, U.-S.; Conte, P.-F.;
Ejlertsen, B.; Bergh, J.; Kaufmann, M.; Holen, I., Adjuvant
bisphosphonates in early breast cancer: consensus
guidance for clinical practice from a European panel. Ann.
Oncol. 2015, 27(3), 379-390.
30.
Wang, R.; Griffin, P. R.; Small, E. C.; Thompson, J. E.,
Mechanism of Janus kinase 3-catalyzed phosphorylation of
a Janus kinase 1 activation loop peptide. Arch. Biochem.
Biophys. 2003, 410 (1), 7-15.
31.
Junankar, S.; Shay, G.; Jurczyluk, J.; Ali, N.; Down, J.;
Pocock, N.; Parker, A.; Nguyen, A.; Sun, S.; Kashemirov, B.;
McKenna, C. E.; Croucher, P. I.; Swarbrick, A.; Weilbaecher,
K.; Phan, T. G.; Rogers, M. J., Real-time intravital imaging
establishes tumor-associated macrophages as the
extraskeletal target of bisphosphonate action in cancer.
Cancer Discov. 2015, 5 (1), 35-42.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20.
Yuen, T.; Stachnik, A.; Iqbal, J.; Sgobba, M.; Gupta,
Y.; Lu, P.; Colaianni, G.; Ji, Y.; Zhu, L.-L.; Kim, S.-M.; Li, J.; Liu,
P.; Izadmehr, S.; Sangodkar, J.; Bailey, J.; Latif, Y.; Mujtaba,
S.; Epstein, S.; Davies, T. F.; Bian, Z.; Zallone, A.; Aggarwal, A.
K.; Haider, S.; New, M. I.; Sun, L.; Narla, G.; Zaidi, M.,
Bisphosphonates inactivate human EGFRs to exert
antitumor actions. Proc. Natl. Acad. Sci. U. S. A. 2014, 111
(50), 17989-17994.
32.
Joyce, J. A.; Pollard, J. W., Microenvironmental
regulation of metastasis. Nat. Rev. Cancer 2009, 9 (4), 239-
252.
33.
tumour-associated macrophages in tumour progression:
implications for new anticancer therapies. J. Pathol. 2002,
196 (3), 254-265.
Bingle, L.; Brown, N. J.; Lewis, C. E., The role of
21.
Stachnik, A.; Yuen, T.; Iqbal, J.; Sgobba, M.; Gupta,
Y.; Lu, P.; Colaianni, G.; Ji, Y.; Zhu, L. L.; Kim, S. M.; Li, J.; Liu,
P.; Izadmehr, S.; Sangodkar, J.; Scherer, T.; Mujtaba, S.;
Galsky, M.; Gomez, J.; Epstein, S.; Buettner, C.; Bian, Z.;
Zallone, A.; Aggarwal, A. K.; Haider, S.; New, M. I.; Sun, L.;
Narla, G.; Zaidi, M., Repurposing of bisphosphonates for the
prevention and therapy of nonsmall cell lung and breast
cancer. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (50), 17995-
8000.
34.
Raikkonen, J.; Crockett, J. C.; Rogers, M. J.;
Monkkonen, H.; Auriola, S.; Monkkonen, J., Zoledronic acid
induces formation of a pro-apoptotic ATP analogue and
isopentenyl pyrophosphate in osteoclasts in vivo and in
MCF-7 cells in vitro. Br. J. Pharmacol. 2009, 157 (3), 427-
435.
35.
Monkkonen, J.; Simila, J.; Rogers, M. J., Effects of
22.
Zhang, Y.; Leon, A.; Song, Y.; Studer, D.; Haase, C.;
tiludronate and ibandronate on the secretion of
proinflammatory cytokines and nitric oxide from
macrophages in vitro. Life Sci. 1998, 62 (8), PL95-102.
Koscielski, L. A.; Oldfield, E., Activity of nitrogen-containing
and non-nitrogen-containing bisphosphonates on tumor
cell lines. J. Med. Chem. 2006, 49 (19), 5804-5814.
36.
Cocco, R.; Tofi, C.; Fioravanti, A.; Nerucci, F.;
23.
Webster, M. R.; Zhao, M.; Rudek, M. A.; Hann, C. L.;
Nannipieri, F.; Zampieri, A.; Rosini, S.; Marcolongo, R.,
Effects of clodronate on synovial fluid levels of some
inflammatory
administration to patients with synovitis secondary to
knee osteoarthritis. Boll. Soc. Ital. Biol. Sper. 1999, 75 (11-
12), 71-76.
Freel Meyers, C. L., Bisphosphonamidate clodronate
prodrug exhibits potent anticancer activity in non-small-
cell lung cancer cells. J. Med. Chem. 2011, 54 (19), 6647-
6656.
mediators,
after
intra-articular
24.
Webster, M. R.; Kamat, C.; Connis, N.; Zhao, M.;
Weeraratna, A. T.; Rudek, M. A.; Hann, C. L.; Freel Meyers, C.
L., Bisphosphonamidate clodronate prodrug exhibits
selective cytotoxic activity against melanoma cell lines. Mol.
Cancer Ther. 2014, 13 (2), 297-306.
37.
Rovetta, G.; Monteforte, P., Efficacy of disodium-
clodronate in the management of joint pain in rheumatoid
arthritis. Six months open study. Minerva. Med. 2003, 94
(5), 353-357.
25.
Xia, Y.; Liu, Y.-L.; Xie, Y.; Zhu, W.; Guerra, F.; Shen,
38.
Wang, C. H.; Shen, Y. C.; Hsieh, J. J.; Yeh, K. Y.;
S.; Yeddula, N.; Fischer, W.; Low, W.; Zhou, X.; Zhang, Y.;
Oldfield, E.; Verma, I. M., A combination therapy for KRAS-
Chang, J. W., Clodronate alleviates cachexia and prolongs
survival in nude mice xenografted with an anaplastic
thyroid carcinoma cell line. J. Endocrinol. 2006, 190 (2),
415-423.
driven
lung
adenocarcinomas
using
lipophilic
bisphosphonates and rapamycin. Sci. Transl. Med. 2014, 6
(263), 263ra161.
39.
Rossini, M.; Viapiana, O.; Ramonda, R.; Bianchi, G.;
26.
Turhanen, P. A., Synthesis of a biologically
Olivieri, I.; Lapadula, G.; Adami, S., Intra-articular
clodronate for the treatment of knee osteoarthritis: dose
ranging study vs hyaluronic acid. Rheumatology (Oxford)
2009, 48 (7), 773-778.
important adenosine triphosphate analogue, ApppD. ACS
Omega 2017, 2 (6), 2835-2838.
27.
Puljula, E.; Turhanen, P. A., Semi-preparative high-
performance countercurrent chromatography method for
the purification of chemically synthesized ATP analogue,
ApppI. J. Chromatogr. B 2017, 1063, 180-182.
40.
Oizumi, T.; Yamaguchi, K.; Funayama, H.; Kuroishi,
T.; Kawamura, H.; Sugawara, S.; Endo, Y., Necrotic actions
of nitrogen-containing bisphosphonates and their
inhibition by clodronate,
bisphosphonate in mice: potential for utilization of
clodronate as combination drug with nitrogen-
containing bisphosphonate. Basic Clin. Pharmacol. Toxicol.
2009, 104 (5), 384-392.
28.
Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M.
a
non-nitrogen-containing
S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J., The
T790M mutation in EGFR kinase causes drug resistance by
increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A.
2008, 105 (6), 2070-2075.
a
a
ACS Paragon Plus Environment